Triple negative breast cancer Based on the characteristics of immunohistochemical staining, breast cancers that are negative for ER, PR and HER2 receptors are called receptor triple negative breast cancers. The typing of breast cancers by gene chip technology revealed that receptor triple negative breast cancers have high concordance with basal-like subtype breast cancers, with early recurrence, rapid progression and short survival. For the treatment of triple negative breast cancers, there is There are no recommended treatment options for triple-negative breast cancer, and the status of targeted therapy in triple-negative breast cancer is unclear. Overview: Breast cancer is one of the most common malignant tumors in women. Every year, about 1.3 million people worldwide are diagnosed with breast cancer, and about 400,000 people die from the disease, and the incidence of breast cancer in China is increasing year by year, and in major cities such as Beijing, Tianjin and Shanghai, the incidence of breast cancer has ranked first among female malignant tumors. Breast cancer is a malignant tumor with highly heterogeneous biological characteristics and can be classified into different subtypes according to its histology, immunohistochemistry and molecular biology techniques. For example, according to histological classification: invasive carcinoma, non-invasive carcinoma, invasive specific carcinoma, invasive non-specific carcinoma, other rare carcinoma. Treatment of receptor triple negative breast cancer: receptor triple negative breast cancer has poor histological grading and poor prognosis, its endocrine therapy and targeted therapy against HER2 are not suitable for this subgroup, chemotherapy is the only systemic treatment, and the current breast cancer treatment guidelines do not have a recommended treatment plan for this subgroup. 1. Choice of cytotoxic drugs: Most patients with triple negative breast cancer have BRCA1 deletion or mutation. Wild-type BRCA1 induces apoptosis and inhibits the estrogen-dependent transcriptional pathway, which is associated with mammary epithelial cell proliferation, and mutations in the gene result in loss of inhibition and oncogenesis. In vitro tests have shown that BRCA1-associated breast cancer is extremely sensitive to drugs that can disrupt DNA structure, such as alkylating agents, mitomycin C, platinum-based drugs, and pegylated glycosides, bleomycin, but shows resistance to mitotic spindle cytotoxic drugs such as paclitaxel and vincristine. 2. Neoadjuvant chemotherapy: chemotherapy for metastatic receptor triple negative breast cancer; high dose chemotherapy; targeted therapy. In conclusion, triple-negative breast cancer is a subtype of breast cancer with unique biological and clinical characteristics, its risk of development and recurrence pattern is different from other subtypes of breast cancer, and its prognosis is poor and often accompanied by BRCA1 mutation. Better prognosis.